A citation-based method for searching scientific literature

Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su, Yu Shyr, D Ross Camidge, Lecia V Sequist, Bonnie S Glisson, Fadlo R Khuri, Edward B Garon, William Pao, Charles Rudin, Joan Schiller, Eric B Haura, Mark Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D Minna, Paul A Bunn. JAMA 2014
Times Cited: 955



Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska, David N Louis, David C Christiani, Jeff Settleman, Daniel A Haber. N Engl J Med 2004
Times Cited: 8417




List of shared articles



Times cited

Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers.
Hiroki Sato, Michael Offin, Daisuke Kubota, Helena A Yu, Clare Wilhelm, Shinichi Toyooka, Romel Somwar, Mark G Kris, Marc Ladanyi. J Thorac Oncol 2021
4

2020 Innovation-Based Optimism for Lung Cancer Outcomes.
Erin L Schenk, Tejas Patil, Jose Pacheco, Paul A Bunn. Oncologist 2021
1


Clinical cancer genomic profiling.
Debyani Chakravarty, David B Solit. Nat Rev Genet 2021
2

Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer.
Vanesa Gregorc, Chiara Lazzari, Mario Mandalá, Stefania Ippati, Alessandra Bulotta, Maria Giulia Cangi, Abdelrahman Khater, Maria Grazia Viganò, Aurora Mirabile, Lorenza Pecciarini,[...]. Cancers (Basel) 2021
2

Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations.
Antonio Passaro, Ilaria Attili, Alessandra Rappa, Davide Vacirca, Alberto Ranghiero, Caterina Fumagalli, Juliana Guarize, Lorenzo Spaggiari, Filippo de Marinis, Massimo Barberis,[...]. Cancers (Basel) 2021
2


Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.
Emma-Anne Karlsen, Sam Kahler, Joan Tefay, Shannon R Joseph, Fiona Simpson. Cells 2021
2

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J W Chen, Tsung-Ying Yang, Gee-Chen Chang. Sci Rep 2021
1

Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency.
Emir Celik, Nilay Sengul Samanci, Mehmet Karadag, Nebi Serkan Demirci, Duygu Ilke Cikman, Sumeyra Derin, Sahin Bedir, Ezgi Degerli, Kerem Oruc, Nihan Senturk Oztas,[...]. J Oncol Pharm Pract 2021
0

Neuregulin Signaling in the Tumor Microenvironment.
Ruxue Jia, Hu Zhao, Shuiliang Wang. Adv Exp Med Biol 2021
0

Treatment Patterns and Survival of Patients With Advanced Non-Small Cell Lung Cancer Guided by Comprehensive Genomic Profiling: Real-World Single-Institute Study in China.
Weize Lv, Hua Cheng, Di Shao, Yajun Wei, Weiping Zhu, Kui Wu, Wenxi Jiang, Liyang Hu, Zhou Sha, Beilong Zhong,[...]. Front Oncol 2021
0

Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals.
M Patricia Rivera, Marjory Charlot, Danielle D Durham, Allison Throneburg, Lindsay M Lane, Pasangi Perera, Teresa D Samulski, Louise M Henderson. Chest 2021
1